![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 19, 2021 8:05:31 AM
The severe acute respiratory syndrome (SARS) outbreak at the end of 2002 was a global infectious disease epidemic. According to the World Health Organization (WHO), over 8,000 people were infected and over 700 died worldwide. The culprit causing the epidemic was the SARS coronavirus (SARS-CoV), which is named for the coronal or crown shape on the outer membrane of the virus.
At the end of 2019, several unidentified pneumonia cases were found in Wuhan, China, which rapidly spread to all parts of the country and multiple countries around the world. These cases and many others that continue to be reported are due to a newly identified coronavirus, SARS-CoV-2, that is currently under intense scientific scrutiny.
Both the number of patients infected and those that have died from the current coronavirus epidemic now exceed the total of those from the SARS outbreak in 2002. The pathogens that caused both outbreaks belong to the Coronaviridae family. The World Health Organization has recently named the current disease outbreak COVID-19. Currently, there are no effective vaccines or treatments available for this virus, though a novel coronavirus vaccine (jointly designed and developed by the Chinese Center for Disease Control and Prevention, Tongji University School of Clinical Medicine and Stemirna Therapeutics) is expected to enter clinical trials in April.
Mouse models play a critical role in both vaccine and drug development. Studies have shown that SARS-CoV enters the human body by binding to human angiotensin-converting enzyme 2 (ACE2). However, due to structural differences in mouse ACE2 compared to human ACE2 proteins, the SARS coronaviruses exhibit poor tropism characteristics for mouse tissues and are inefficient at infecting mice. As a result of this poor viral tissue tropism in mice, commonly used wild-type mouse strains are not optimal for studying infections of the newly discovered coronavirus. Fortunately, a transgenic model is now available to fill the unmet need for an in vivo experimental platform for COVID-19 research.
Introducing the K18-hACE2 transgenic mouse for coronavirus research
In 2007, Dr. Paul McCray, et al from the University of Iowa published a study in which they introduced a vector carrying a human ACE2-coding sequence into wild-type mice and subsequently developed a successful hACE2 transgenic mouse strain. ACE2 expression, which is regulated by the human cytokeratin 18 (K18) promoter in epithelial cells, was observed in the initially infected airway epithelial cells. Studies showed that the K18-hACE2 transgenic mouse infected with a human SARS-CoV strain via intranasal inoculation would not survive.
The infection would begin in the airway epithelium, spread to the alveoli and finally out of the lungs to the brain. The infection causes infiltration of macrophages and lymphocytes in the lungs and up-regulation of pro-inflammatory cytokines and chemokines in the lungs and brain. Three to five days following infection, K18-hACE2 mice began to lose weight and become lethargic with labored breathing. All died within seven days. These observations support that transgene expression of hACE2 in epithelial cells can convert moderate SARS-CoV infection into a fatal disease.
Recent SBFM News
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 08/20/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:05:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/16/2024 09:00:24 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:05:09 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 07/11/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:05:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/05/2024 09:37:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/23/2024 09:03:01 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/21/2024 09:28:39 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/21/2024 01:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 04:39:32 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:53:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/14/2024 04:18:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:04:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:17:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:17:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 05:38:24 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2024 01:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:59:51 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM